american oriental bioenginee (AOBI) Snapshot

American Oriental Bioengineering Inc. filed its 10-K on Jun 11, 2013 for the period ending Dec 31, 2012. In this report its auditor, Weinberg & Company, P.A., gave an unqualified opinion expressing doubt that the company can continue as a going concern.

The Law Offices of Todd M. Garber announced that a class action lawsuit has been filed in the United States District Court for the Central District of California on behalf of a class comprising all purchasers of the securities of American Oriental Bioengineering Inc. between November 9, 2009 and June 15, 2012, inclusive (Class Period). The complaint alleges that the company and certain of its executive officers and directors made false and misleading statements and/or failed to disclose material adverse facts about companies operations and financial performance. Specifically, during the Class Period the defendants misrepresented and/or failed to disclose that: certain of the company's capsule products maintained chrome levels far exceeding humanly tolerable limits; the company's financial statements contained material inconsistencies; the company's internal controls over financial reporting were deficient; and as a result of the foregoing, the company's statements were materially false and misleading at all relevant times.

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the Central District of California on behalf of a class comprising all persons who purchased or otherwise acquired the securities of American Oriental Bioengineering Inc. between November 9, 2009 and June 15, 2012, inclusive. AOBI engages in the development, manufacture and commercialization of pharmaceutical and healthcare products. The Complaint alleges that the defendants made false and misleading statements and/or failed to disclose material adverse facts about AOBI's operations and financial performance. Specifically, defendants misrepresented and/or failed to disclose that: certain of the Company's capsule products maintained chrome levels far exceeding humanly tolerable limits; the Company's financial statements contained material inconsistencies; the Company's internal controls over financial reporting were deficient; and, as a result of the foregoing, the Company's statements were materially false and misleading at all relevant times. No class has yet been certified in the above action.